KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
20 hedge funds and large institutions have $51.4M invested in KalVista Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 9 closing their positions.
1,855% more capital invested
Capital invested by funds: $2.63M → $51.4M (+$48.8M)
73.83% more ownership
Funds ownership: 0% → 73.83% (+74%)
5% less funds holding
Funds holding: 21 → 20 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$21.4M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
+$19M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.36M |
| 4 |
VMI
VHCP Management II
New York
|
+$1.63M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$112K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$50.6K |
| 3 |
AFG
Albion Financial Group
Salt Lake City,
Utah
|
-$45K |
| 4 |
Goldman Sachs
New York
|
-$44K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$30K |
KALV Hedge Fund Activity: Q4 2016 in Review
20 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2016, worth a combined $51.4M — up 1,855% from $2.63M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of KALV and 8 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 2 added.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $21.4M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $112K sold.
- 20 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2016, down from 21 in Q3 2016.
- Funds reported $51.4M of KalVista Pharmaceuticals stock for Q4 2016, up 1,855% quarter-over-quarter.
- 8 funds opened new KalVista Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of -1 holder.
- The largest KalVista Pharmaceuticals buyer in Q4 2016 was Novo Holdings A/S, an estimated $21.4M added.
- The largest KalVista Pharmaceuticals seller in Q4 2016 was Renaissance Technologies, an estimated $112K sold.
Based on aggregated 13F filings for Q4 2016.